EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders

This is an investigator-initiated, open-label, single-arm, dose-escalation exploratory study to evaluate the safety, tolerability, and preliminary efficacy of EBV-AST cell injection in adults with EBV-associated lymphoproliferative disorders, including post-transplant lymphoproliferative disease (PTLD) and EBV-positive lymphomas. Participants will receive EBV-AST cell infusions intravenously every 2 weeks for up to 3 infusions at escalating dose levels. The primary objective is to assess safety and determine a potential optimal biologically active dose. Secondary objectives include preliminary

Trial Details

NCT ID
NCT07450391
Phase
PHASE1 / PHASE2
Sponsor
Daihong Liu
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • EBV-AST Cell Injection
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Able to understand and voluntarily sign written informed consent.
  • Age 18 to 75 years, inclusive.
  • HLA genotype matches at least one of the following: HLA-A02:01, HLA-A11:01, or HLA-A\*24:02.
  • Karnofsky Performance Status (KPS) ≥ 70.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →